Literature DB >> 24768609

Epicardial linear electroporation ablation and lesion size.

Kars Neven1, Vincent van Driel2, Harry van Wessel3, René van Es2, Pieter A Doevendans4, Fred Wittkampf2.   

Abstract

BACKGROUND: Electroporation can be used as a nonthermal method to ablate myocardial tissue. However, like with all electrical ablation methods, determination of the energy supplied into the myocardium enhances the clinically required controllability over lesion creation.
OBJECTIVE: To investigate the relationship between the magnitude of epicardial electroporation ablation and the lesion size using an electrically isolating linear suction device.
METHODS: In 5 pigs (60-75 kg), the pericardium was opened after medial sternotomy. A custom linear suction device with a single 35 × 6-mm electrode inside a 42-mm-long and 7-mm-wide plastic suction cup was used for electroporation ablation. Single cathodal applications of 30, 100, or 300 J were delivered randomly at 3 different epicardial left ventricular sites. Coronary angiography was performed before ablation, immediately after ablation, and after 3 months survival. Lesion size was measured histologically after euthanization.
RESULTS: The mean depth of 30, 100, and 300 J lesions was 3.2 ± 0.7, 6.3 ± 1.8, and 8.0 ± 1.5 mm, respectively (P = .0003). The mean width of 30, 100, and 300 J lesions was 10.1 ± 0.8, 15.1 ± 1.5, and 17.1 ± 1.3 mm, respectively (P<.0001). Significant tissue shrinkage was observed at the higher energy levels. No luminal arterial narrowing was observed after 3 months: 2.3 ± 0.3 mm vs 2.3 ± 0.4 mm (P = .85).
CONCLUSION: The relationship between the amount of electroporation energy delivered through a linear suction device with a single linear electrode and the mean myocardial lesion size is significant in the absence of major adverse events or permanent damage to the coronary arteries.
Copyright © 2014 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Coronary artery; Epicardium; Irreversible electroporation; Safety

Mesh:

Year:  2014        PMID: 24768609     DOI: 10.1016/j.hrthm.2014.04.031

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  8 in total

Review 1.  Better Lesion Creation And Assessment During Catheter Ablation.

Authors:  Saurabh Kumar; Chirag R Barbhaiya; Samuel Balindger; Roy M John; Laurence M Epstein; Bruce A Koplan; Usha B Tedrow; William G Stevenson; Gregory F Michaud
Journal:  J Atr Fibrillation       Date:  2015-10-31

2.  Predicting irreversible electroporation-induced tissue damage by means of magnetic resonance electrical impedance tomography.

Authors:  Matej Kranjc; Simona Kranjc; Franci Bajd; Gregor Serša; Igor Serša; Damijan Miklavčič
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

3.  Intrapulmonary Vein Ablation Without Stenosis: A Novel Balloon-Based Direct Current Electroporation Approach.

Authors:  Chance M Witt; Alan Sugrue; Deepak Padmanabhan; Vaibhav Vaidya; Sarah Gruba; James Rohl; Christopher V DeSimone; Ammar M Killu; Niyada Naksuk; Joanne Pederson; Scott Suddendorf; Dorothy J Ladewig; Elad Maor; David R Holmes; Suraj Kapa; Samuel J Asirvatham
Journal:  J Am Heart Assoc       Date:  2018-07-09       Impact factor: 5.501

4.  Endocardial ventricular pulsed field ablation: a proof-of-concept preclinical evaluation.

Authors:  Jacob S Koruth; Kenji Kuroki; Jin Iwasawa; Raju Viswanathan; Richard Brose; Eric D Buck; Elina Donskoy; Srinivas R Dukkipati; Vivek Y Reddy
Journal:  Europace       Date:  2020-03-01       Impact factor: 5.214

Review 5.  Pulsed Field Ablation to Treat Atrial Fibrillation: A Review of the Literature.

Authors:  Antonio Di Monaco; Nicola Vitulano; Federica Troisi; Federico Quadrini; Imma Romanazzi; Valeria Calvi; Massimo Grimaldi
Journal:  J Cardiovasc Dev Dis       Date:  2022-03-24

6.  Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF).

Authors:  Emmanuel Ekanem; Vivek Y Reddy; Boris Schmidt; Tobias Reichlin; Kars Neven; Andreas Metzner; Jim Hansen; Yuri Blaauw; Philippe Maury; Thomas Arentz; Philipp Sommer; Ante Anic; Frederic Anselme; Serge Boveda; Tom Deneke; Stephan Willems; Pepijn van der Voort; Roland Tilz; Moritoshi Funasako; Daniel Scherr; Reza Wakili; Daniel Steven; Josef Kautzner; Johan Vijgen; Pierre Jais; Jan Petru; Julian Chun; Laurent Roten; Anna Füting; Andreas Rillig; Bart A Mulder; Arne Johannessen; Anne Rollin; Heiko Lehrmann; Christian Sohns; Zrinka Jurisic; Arnaud Savoure; Stephanes Combes; Karin Nentwich; Melanie Gunawardene; Alexandre Ouss; Bettina Kirstein; Martin Manninger; Jan Eric Bohnen; Arian Sultan; Petr Peichl; Pieter Koopman; Nicolas Derval; Mohit K Turagam; Petr Neuzil
Journal:  Europace       Date:  2022-09-01       Impact factor: 5.486

7.  Establishing electroporation thresholds for targeted cell specific cardiac ablation in a 2D culture model.

Authors:  Sahar Avazzadeh; Mahshid H Dehkordi; Peter Owens; Amirhossein Jalali; Barry O'Brien; Ken Coffey; Martin O'Halloran; Howard O Fernhead; David Keane; Leo R Quinlan
Journal:  J Cardiovasc Electrophysiol       Date:  2022-08-16       Impact factor: 2.942

8.  Elimination of Purkinje Fibers by Electroporation Reduces Ventricular Fibrillation Vulnerability.

Authors:  Christopher Livia; Alan Sugrue; Tyra Witt; Murray D Polkinghorne; Elad Maor; Suraj Kapa; Helge I Lehmann; Christopher V DeSimone; Atta Behfar; Samuel J Asirvatham; Christopher J McLeod
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.